Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Postmarketing Trials For Blincyto Likely To Form Stringent Dataset On Minimal Residual Disease

Executive Summary

US FDA requiring randomized trials in adults and children as part of Blincyto’s supplemental accelerated approval in minimal residual disease; along with Amgen's data, agency will have results from NCI-funded trials to evaluate efficacy.

Advertisement

Related Content

Janssen Exec On Speeding Earlier Myeloma Interventions To Market With Key Biomarker
Amgen's Blincyto Has 'Potential Benefit' For MRD ALL, But Approval Chances Remain Unclear
Amgen Will Try To Convince ODAC Of Minimal Disease Endpoint To Show Blincyto's Efficacy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel